Welcome to Scribd, the world's digital library. Read, publish, and share books and documents. See more
Buy Now $4.99
Standard view
Full view
of .
Look up keyword
Like this
1Activity
P. 1
Lack of absorption of extended-release pramipexole in a patient with early parkinson´s disease

Lack of absorption of extended-release pramipexole in a patient with early parkinson´s disease

Ratings: (0)|Views: 12|Likes:
Published by iMedPub
Pramipexole is a nonergot dopamine agonist indicated for treating Parkinson’s
disease (PD) and restless legs syndrome. Pramipexole extended release (ER) is a
recently developed once-daily formulation which has demonstrated noninferiority
compared with pramipexole immediate release (IR) in the treatment of early
[1] and advanced PD [2]. Compared with the immediate release (IR) formulation,
the ER formulation offers some advantages, including the potential for improved
compliance owing to its simple once-daily dosing regimen and steadier plasma
levels over 24 h [3]. According to data from clinical trials, both formulations have
a similar digestive absorption with a bioavailability of more than 90%, and the
overnight switch from pramipexole IR three times a day to pramipexole ER once
daily at unchanged dosage in PD patients has been shown to be successful in
more than 80% of patients, with minor adjustments needed in the other patients
[4]. Here we report the case of a patient with mild PD, unsuccessfully treated with
pramipexole ER due to lack of digestive absorption of the drug.
Pramipexole is a nonergot dopamine agonist indicated for treating Parkinson’s
disease (PD) and restless legs syndrome. Pramipexole extended release (ER) is a
recently developed once-daily formulation which has demonstrated noninferiority
compared with pramipexole immediate release (IR) in the treatment of early
[1] and advanced PD [2]. Compared with the immediate release (IR) formulation,
the ER formulation offers some advantages, including the potential for improved
compliance owing to its simple once-daily dosing regimen and steadier plasma
levels over 24 h [3]. According to data from clinical trials, both formulations have
a similar digestive absorption with a bioavailability of more than 90%, and the
overnight switch from pramipexole IR three times a day to pramipexole ER once
daily at unchanged dosage in PD patients has been shown to be successful in
more than 80% of patients, with minor adjustments needed in the other patients
[4]. Here we report the case of a patient with mild PD, unsuccessfully treated with
pramipexole ER due to lack of digestive absorption of the drug.

More info:

Published by: iMedPub on Jan 04, 2014
Copyright:Attribution Non-commercial
List Price: $4.99 Buy Now

Availability:

Read on Scribd mobile: iPhone, iPad and Android.
See more
See less

05/22/2014

$4.99

USD

You're Reading a Free Preview
Page 2 is not shown in this preview.

You're Reading a Free Preview

Download
scribd
/*********** DO NOT ALTER ANYTHING BELOW THIS LINE ! ************/ var s_code=s.t();if(s_code)document.write(s_code)//-->